CEO: | Mark Crossley |
CFO & Executive Director: | Ryan Preblick |
Chairman: | Graham Hetherington |
Independent Non-Executive Director: | Peter Bains |
Independent Non-Executive Director: | Barbara Ryan |
Independent Non-Executive Director: | Jo Le Couilliard |
Independent Non-Executive Director: | Keith Humphreys |
Independent Non-Executive Director: | Mark Stejbach |
Senior Independent Director: | Juliet Thompson |
Non-Executive Dir: | Jerome Lande |
Address: | 234 Bath Road, Slough, Berkshire, United Kingdom, SL1 4EE |
Website: | http://www.Indivior.com |
Sector: | Pharma and Biotech(LSE) |
Index: | FTSE 250, FTSE 350, FTSE All-Share |
Overseas Listings: | BATSLON:INDVL |
ISIN: | GB00BN4HT335 |
Currency | UK Pounds |
Share Price | 1,524.00p |
Change Today | -27.00p |
% Change | -1.74 % |
52 Week High | 1,885.00 |
52 Week Low | 1,135.00 |
Volume | 178,070 |
Shares Issued | 135.60m |
Market Cap | £2,066.51m |
RiskGrade | 314 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 1 |
Buy | 2 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 3 |
No dividends found |
Time | Volume / Share Price |
16:35 | 59 @ 1,524.00p |
16:35 | 104,373 @ 1,524.00p |
16:35 | 71 @ 1,524.00p |
16:35 | 1,381 @ 1,524.00p |
16:35 | 217 @ 1,524.00p |
CEO | Mark Crossley |
Chair | Graham Hetherington |
You are here: research